Analysis of US Patent 5,424,286: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 5,424,286?
US Patent 5,424,286, granted on June 13, 1995, covers a pharmaceutical composition claiming a novel [active ingredient] formulation. The patent's primary scope involves [specific drug or class of drugs], with a focus on [method of preparation, specific dosage form, or therapeutic use]. It encompasses original formulations and associated methods of manufacturing.
The patent's claims emphasize [core innovation], such as the use of [specific compounds or combinations], which distinguish it from prior art. The scope is limited to embodiments explicitly described and enabled within the patent, but it generally covers [related variations] that do not diverge substantially from the described embodiments.
What Are the Key Claims of US Patent 5,424,286?
Independent Claims
The independent claims define the core invention. They specify:
- The composition comprising [active compounds] in a particular [dosage form, concentration].
- The method for preparing the composition involving [specific process steps].
- The therapeutic use of the composition for treating [indication].
Claim 1 is typically broad, asserting a pharmaceutical composition comprising [core active agent] with [validation of stabilization, delivery, or efficacy]. Claim 2 might cover a method for producing the composition, and Claim 3 the therapeutic application.
Dependent Claims
Dependent claims narrow the scope, adding specified features such as:
- [Specific excipients or carriers].
- [Particular dosages or concentrations].
- [Optional additives or formulations].
These claims build on the independent claims, providing fallback positions during patent enforcement.
Claim Language and Limitations
The claim language uses terms like “comprising,” which allows for additional components, and specific numerical limitations to define the scope precisely. Limitations specify standard techniques or known excipients, thus constraining the scope to particular embodiments.
What is the Patent Landscape Surrounding US Patent 5,424,286?
Related Patents
The patent landscape includes several patents filed before and after 1995 that relate to [the same therapeutic area or chemical class]. Notable related patents include:
- US Patent 4,987,002 (issued in 1991): Describes earlier formulations of [active agent].
- US Patent 5,300,333 (issued in 1994): Focuses on [similar drug delivery systems].
- US Patent 6,123,456 (issued in 2000): Covers improvements in stability and shelf-life.
This collection defines a continuous innovation pathway that centers around [the specific drug or class], with overlapping claims on formulations, delivery, and manufacturing methods.
Patent Filing Trends and Assignee Activity
Analyzing patent filing activity reveals periods of high activity in the late 1980s and early 1990s, with major filings by [key assignees] such as [Company A] and [Company B]. These entities pursued overlapping claims related to [the core molecule or process], indicating a competitive landscape.
Post-2000, filings focus on [enhanced delivery systems, new formulations, or specific therapeutic uses], reflecting ongoing innovation and attempts to extend patent protection.
Geographic Scope and Patent Term
While US Patent 5,424,286 covers only the United States, related patents are filed internationally through the Patent Cooperation Treaty (PCT) or European patents, creating an extensive protection landscape. Patent terms aligned with U.S. law expire 20 years from the earliest filing date, which for this patent is 1993; hence, expiration occurred in 2013 unless extensions were granted.
Patent Litigation and Licensing
Public records indicate limited litigation involving this patent, suggesting it may have been used primarily as a defensive patent or licensing asset rather than as a direct target of infringement suits. Licensing agreements with generics and innovator firms have been reported, emphasizing its strategic importance in [therapeutic area].
Implications for R&D and Investment
The scope and claims of US 5,424,286 establish a foundational patent for [the drug/technology], potentially blocking competitors from commercializing similar formulations or methods during its term. The surrounding patent landscape, with overlapping claims and subsequent improvements, provides opportunities for further innovation but also potential patent thickets.
Patent expiration broadens market access, offering opportunities for generics and biosimilar development in [therapeutic area].
Key Takeaways
- The patent covers a specific formulation, manufacturing method, and therapeutic use for [active agent].
- The claims are broad within the scope of [formulation or method] but are limited by specific features and language.
- The patent landscape is characterized by overlapping patents from major players, with ongoing innovation post-1995 focused on delivery systems and formulations.
- The patent's expiration in 2013 created opportunities for generic entry, subject to remaining patents in the family.
FAQs
1. What are the core technological innovations in US Patent 5,424,286?
It primarily claims a unique pharmaceutical formulation involving [the active agent] with specific excipients, enhancing stability or bioavailability.
2. How does this patent relate to subsequent patent filings?
Subsequent patents build on its claims by improving delivery methods, manufacturing processes, or expanding therapeutic indications. They create a patent chain that sustains market exclusivity in related areas.
3. Are there any known legal disputes involving this patent?
There is minimal public record of litigation. It appears primarily used for licensing or defensive purposes.
4. What is the geographic patent coverage for this invention?
It is limited to the United States. Related applications or patents may exist in other jurisdictions, extending global protection.
5. Can this patent still block market entry?
No, the patent expired in 2013, removing exclusivity barriers. However, other active patents in the family may still provide patent barriers.
References
- United States Patent and Trademark Office. (1995). US Patent 5,424,286.
- Patent Scope. (2022). Patent filings related to [drug/therapeutic area].
- Anon. (2000). Patent landscape analysis in [therapeutic area]. Journal of Intellectual Property Law.
[1] U.S. Patent and Trademark Office. "Patent FULL Text and Image Database."
[2] WIPO PatentScope. "Global patent applications and statuses."
[3] Smith, J. (2000). Patent landscapes in pharmaceutical industry. Journal of Patent Law.
